Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolphin: Durvalumab + Radiochemotherapy in Limited Disease SCLC
NCT04602533Phase 2Active, not recruiting
- Start
- Dec 2020
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC). Started Dec 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04602533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602533.